Addex Therapeutics Ltd (ADXN):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Addex Therapeutics Ltd (ADXN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10006
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:37
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スイス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Addex Therapeutics Ltd (Addex) develops orally available, small molecule allosteric modulators for neurological disorders. The company’s product pipeline consists of its lead products, dipraglurant (mGluR5 negative allosteric modulator or NAM) to treat Parkinson’s disease levodopa-induced dyskinesia (PD-LID) and rare forms of dystonia; and ADX71149 (mGluR2 positive allosteric modulator or PAM) for the treatment of epilepsy. It also conducts clinical and preclinical development of drug candidates for indications such as addiction, Charcot-Marie-Tooth Type 1a (CMT1A) disease, spasticity in patients with multiple sclerosis (MS), pain, overactive bladder, autism and other disorders, Parkinson’s disease, anxiety, resistant depression, cognitive deficits and psychosomatic disorders. Addex is headquartered in Plan-les-Ouates, Geneva, Switzerland.

Addex Therapeutics Ltd (ADXN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Addex Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Addex Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Addex Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Addex Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Addex Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Addex Therapeutics Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Private Equity 10
New Enterprise Associates and New Leaf Venture Partners Invest USD43 Million in Addex Therapeutics 10
Partnerships 12
Addex Therapeutics Enters into Partnership with National Institute on Alcohol Abuse and Alcoholism 12
Addex Therapeutics Enters into Partnership with National Institute on Drug Abuse 13
Addex Therapeutics And Viva Biotech Partner To Advance Allosteric Modulators Targeting Adenosine 2A Receptor 14
Addex Therapeutics Plans To Enter Into Co-Development Agreement For Dipraglurant 15
Licensing Agreements 16
Indivior Enters into Licensing Agreement with Addex Pharma 16
Pierre Fabre Pharma Enters into Licensing Agreement with Addex Therapeutics 17
Equity Offering 18
Addex Therapeutics Raises USD3 Million in Private Placement of Shares 18
Addex Therapeutics Raises Funds through Private Placement of Shares 19
Addex Therapeutics Raises USD2.8 Million in Private Placement of Shares 20
Addex Therapeutics Completes Private Placement Of Shares For US$3.5 Million 21
Addex Therapeutics Completes Private Placement Of Shares For US$11 Million 23
Addex Therapeutics Ltd – Key Competitors 24
Addex Therapeutics Ltd – Key Employees 25
Addex Therapeutics Ltd – Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Recent Developments 27
Financial Announcements 27
Sep 28, 2018: Addex reports 2018 half-year financial results and provides corporate update 27
Apr 30, 2018: Addex Announces 2017 Full Year Results 28
Sep 26, 2017: Addex Therapeutics Reports First Half 2017 Operating Highlights and Financial Results 30
Apr 05, 2017: Addex Therapeutics Provides Corporate Update and Reports 2016 Financial Results 31
Corporate Communications 32
Feb 07, 2018: Addex Appoints Jean-Philippe Rocher as Co-Head of Discovery and Member of the Executive Management 32
Sep 18, 2017: Addex Makes Changes to Executive Management Team 33
Product News 34
01/31/2017: Addex Awarded $835,000 Grant from Michael J. Fox Foundation to Advance TrkB PAMs for the Treatment of Parkinson’s Disease 34
Other Significant Developments 35
Mar 20, 2018: Swiss Takeover Board Validates New Article 39 (Opting-Out Provision) of Addex Articles of Association 35
Mar 19, 2018: Addex Shareholders Approved all Board Proposals at Extraordinary General Meeting 36
Appendix 37
Methodology 37
About GlobalData 37
Contact Us 37
Disclaimer 37

List of Tables
Addex Therapeutics Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Addex Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Addex Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Addex Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Addex Therapeutics Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Addex Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
New Enterprise Associates and New Leaf Venture Partners Invest USD43 Million in Addex Therapeutics 10
Addex Therapeutics Enters into Partnership with National Institute on Alcohol Abuse and Alcoholism 12
Addex Therapeutics Enters into Partnership with National Institute on Drug Abuse 13
Addex Therapeutics And Viva Biotech Partner To Advance Allosteric Modulators Targeting Adenosine 2A Receptor 14
Addex Therapeutics Plans To Enter Into Co-Development Agreement For Dipraglurant 15
Indivior Enters into Licensing Agreement with Addex Pharma 16
Pierre Fabre Pharma Enters into Licensing Agreement with Addex Therapeutics 17
Addex Therapeutics Raises USD3 Million in Private Placement of Shares 18
Addex Therapeutics Raises Funds through Private Placement of Shares 19
Addex Therapeutics Raises USD2.8 Million in Private Placement of Shares 20
Addex Therapeutics Completes Private Placement Of Shares For US$3.5 Million 21
Addex Therapeutics Completes Private Placement Of Shares For US$11 Million 23
Addex Therapeutics Ltd, Key Competitors 24
Addex Therapeutics Ltd, Key Employees 25
Addex Therapeutics Ltd, Other Locations 26
Addex Therapeutics Ltd, Subsidiaries 26

List of Figures
Addex Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Addex Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Addex Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Addex Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Addex Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Addex Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Addex Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Addex Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Addex Therapeutics Ltd (ADXN):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Paranta Biosciences Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Paranta Biosciences Ltd (Paranta Biosciences) is a biopharmaceutical company that develops bio-therapeutics for the treatment of inflammatory and fibrotic diseases. The company develops product candidate PB01, a recombinant human follistatin-288 used for the treatment of cystic fibrosis lung …
  • Archroma Pakistan Ltd. (ARPL):企業の財務・戦略的SWOT分析
    Archroma Pakistan Ltd. (ARPL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Admedus Ltd (AHZ):企業の財務・戦略的SWOT分析
    Admedus Ltd (AHZ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Bracco SpA:企業の戦略的SWOT分析
    Bracco SpA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Corcept Therapeutics Inc (CORT):企業の財務・戦略的SWOT分析
    Corcept Therapeutics Inc (CORT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Energy XXI Gulf Coast Inc (EGC):石油・ガス:M&Aディール及び事業提携情報
    Summary Energy XXI Gulf Coast Inc (Energy XXI) is an oil and gas company that explores and develops oil and natural gas assets. The company’s projects include West Delta, South Timbalier, South Pass, Main Pass, and Ship Shoal. Its West Delta property is located 28 miles offshore of Grand Isle, Louis …
  • Lumenis Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Lumenis Ltd (Lumenis), a subsidiary of XIO Group, is an energy-based medical device company for aesthetic, surgical and ophthalmic applications in the field of minimally invasive clinical solutions. It manufactures and distributes medical and aesthetic lasers and light-based systems. Its maj …
  • BBVA Banco Frances S.A.:企業の戦略・SWOT・財務分析
    BBVA Banco Frances S.A. - Strategy, SWOT and Corporate Finance Report Summary BBVA Banco Frances S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Future Plc (FUTR):企業の財務・戦略的SWOT分析
    Summary Future Plc (Future) is a media company that offers media and digital business solutions various customers. The company offers its services in various areas such as technology, creative, photography and design, games, advertising and film and music. It provides licensing and syndication, expo …
  • PT Dirgantara Indonesia:企業の戦略・SWOT・財務情報
    PT Dirgantara Indonesia - Strategy, SWOT and Corporate Finance Report Summary PT Dirgantara Indonesia - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • HHV Solar Technologies Ltd:電力:M&Aディール及び事業提携情報
    Summary HHV Solar Technologies Ltd (HHV Solar), a subsidiary of Swelect Energy Systems Ltd, is a renewable energy company that manufactures and markets silicon photovoltaic solar modules. The company's modules include monocrystalline solar photovoltaic modules, multi-crystalline solar photovoltaic m …
  • Interglobe Aviation Limited:企業の戦略・SWOT・財務情報
    Interglobe Aviation Limited - Strategy, SWOT and Corporate Finance Report Summary Interglobe Aviation Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • ACEA Biosciences Inc:医療機器:M&Aディール及び事業提携情報
    Summary ACEA Biosciences Inc (ACEA) is a biotechnology company that development and commercialization of cell analysis instruments for life science research and clinical diagnostics. The company's products include impedance-based, label-free, and real-time cell analysis systems, benchtop flow cytome …
  • Alcazar Energy Ltd-エネルギー分野:企業M&A・提携分析
    Summary Alcazar Energy Ltd (Alcazar Energy) is a renewable energy company which develops and produces power generation projects with focus on solar photovoltaic (PV) and onshore wind technologies. The company specializes in origination, development, structuring, acquisition and operation of renewabl …
  • Sierra Wireless Inc (SW):企業の財務・戦略的SWOT分析
    Sierra Wireless Inc (SW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Takuma Co Ltd (6013):企業の財務・戦略的SWOT分析
    Takuma Co Ltd (6013) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Verastem Inc (VSTM):製薬・医療:M&Aディール及び事業提携情報
    Summary Verastem Inc (Verastem) is a clinical-stage biopharmaceutical company with focus on the discovery, development and commercialization of drugs to treat cancer. The company’s lead product candidates include duvelisib, defactinib (VS-6063), FAK inhibitor (VS-4718) and PI3K/mTOR inhibitor (VS-55 …
  • Nikon Corporation:戦略・SWOT・企業財務分析
    Nikon Corporation - Strategy, SWOT and Corporate Finance Report Summary Nikon Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • HSBC Trinkaus & Burkhardt AG (TUB):企業の財務・戦略的SWOT分析
    HSBC Trinkaus & Burkhardt AG (TUB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • TAXIS Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary TAXIS Pharmaceuticals Inc (TAXIS Pharma) is a biopharmaceutical company that treats, reduce and eliminates the threat of current and emergent antimicrobial resistance across a range of infectious diseases. It research new classes of antibiotic agents to treat life-threatening and multidrug-r …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆